2). These enzymes catalyze the formation of thioether linkages between the C1 atom of farnesyl (15-carbon by FTase) or geranylgeranyl (20-carbon by GGTase-I and -II) isoprenoid lipids and cysteine residues at or near the C terminus of protein acceptors. Protein substrates of the prenyltransferases include Ras, Rho, Rab, other Ras-related small GTP-binding proteins, ␥ subunits of heterotrimeric G-proteins, nuclear lamins, centromeric proteins, and many proteins involved in visual signal transduction (2, 3). The attached lipid is required for proper functioning of the modified protein by mediating membrane associations and specific protein-protein interactions. FTase and GGTase-I, which are collectively known as the CaaX prenyltransferases, attach their respective isoprenoid to the cysteine residue of a C-terminal CaaX motif (C, cysteine; a, typically an aliphatic residue; X, C-terminal residue). GGTase-II attaches geranylgeranyl groups to two C-terminal cysteine residues in the Rab family of Rasrelated GTPases.
M
any intracellular proteins are posttranslationally modified by the attachment of lipids (1) . Protein farnesyltransferase (FTase), geranylgeranyltransferase type-I (GGTase-I), and geranylgeranyltransferase type-II (Rab geranylgeranyltransferase, GGTase-II) constitute the protein prenyltransferase family of lipid modifying enzymes (reviewed in ref. 2) . These enzymes catalyze the formation of thioether linkages between the C1 atom of farnesyl (15-carbon by FTase) or geranylgeranyl (20-carbon by GGTase-I and -II) isoprenoid lipids and cysteine residues at or near the C terminus of protein acceptors. Protein substrates of the prenyltransferases include Ras, Rho, Rab, other Ras-related small GTP-binding proteins, ␥ subunits of heterotrimeric G-proteins, nuclear lamins, centromeric proteins, and many proteins involved in visual signal transduction (2, 3) . The attached lipid is required for proper functioning of the modified protein by mediating membrane associations and specific protein-protein interactions. FTase and GGTase-I, which are collectively known as the CaaX prenyltransferases, attach their respective isoprenoid to the cysteine residue of a C-terminal CaaX motif (C, cysteine; a, typically an aliphatic residue; X, C-terminal residue). GGTase-II attaches geranylgeranyl groups to two C-terminal cysteine residues in the Rab family of Rasrelated GTPases.
Ras must be associated with the plasma membrane for proper functioning in the signal transduction pathway. Prenylation of Ras is required for this subcellular localization and is essential for the transforming activity of oncogenic variants of Ras (4) (5) (6) . FTase is therefore a potential target for anticancer therapeutics. A critical advance in the development of FTase inhibitors was the finding that tetrapeptides that conformed to the CaaX sequence motif are competitive inhibitors (7) . Surprisingly, a subset of these tetrapeptides (e.g., CVFM) are not farnesylated (8) . Two features were identified as dominant determinants for the lack of farnesylation: a positively charged N terminus and an aromatic residue at the a 2 position (9) . The distinction between competitive inhibitors that are competent substrates and non-substrate inhibitors is an important one, because farnesylation of the competitive inhibitor decreases their affinity for the enzyme, thereby reducing potency (10) . These findings led to the design of several peptidomimetic compounds based on the CaaX motif (reviewed in ref. 11). The initial hurdles of low cell permeability and susceptibility to proteolytic degradation inherent to peptidebased compounds were overcome by the synthesis of ester prodrugs, such as L-744,832 ( Fig. 1) , which inhibited the growth of more than 70% of tumor cell lines (12) and caused tumor regression in H-ras transformed mice, without systemic toxicity (13) . Numerous inhibitors of FTase are now in clinical trials for the treatment of human cancer (reviewed in ref. 14) . L-744,832 is the isopropyl ester prodrug of L-739,750 ( Fig. 1; ref. 15 ), the peptidomimetic compound used in the structures presented in this paper, and was the first inhibitor of FTase to demonstrate tumor regression in animals (13) .
The three-dimensional structures of FTase-bound peptidomimetics were initially characterized by NMR spectroscopy. Twodimensional transferred nuclear Overhauser effect (TRNOE) experiments indicated that the peptide backbones of a CIFM peptide-based compound and the peptide CVWM adopt conformations similar to a ␤-turn when bound to FTase (16) . This information was used to design conformationally constrained peptidomimetic compounds that are very potent inhibitors of FTase (11) . It was therefore surprising to find that, in crystal structures of FTase complexed with peptide substrates and farnesyl diphosphate analogs, the CaaX motifs adopted an extended conformation (17, 18) rather than a ␤-turn. In the crystal structures, the cysteine thiolate of the CaaX motif coordinates the catalytic zinc ion, consistent with UV-visible spectroscopic solution studies (19, 20) . However, removal of the zinc ion converts the extended conformation to a ␤-turn in the crystal structure (18) . This result suggests that the ␤-turn conformation observed by NMR studies represents a state in which the cysteine is not coordinated to the zinc ion.
Here, we present three crystal structures of FTase complexes (which include the first structure of human FTase) that provide a molecular basis for the mode of action of CaaX tetrapeptide inhibitors and their mimetics. We find that tetrapeptides adopt an extended conformation, rather than a ␤-turn, and we suggest a basis for the distinction between substrate and non-substrate inhibition.
Materials and Methods
Sample Preparation. To obtain heterodimeric human FTase in Escherichia coli, the two subunits were expressed as a translationally coupled operon under transcriptional control by the bacteriophage T7 promoter in the plasmid pT5T (21) . Translational coupling was achieved by placing the ␣ subunit coding sequence upstream of the ␤ subunit coding sequence. A microtubule epitope, Glu-Glu-Phe, was fused to the carboxyl terminus of the ␣ subunit, allowing affinity purification of the heterodimer from E. coli extracts, similar to a GGTase-I expression system (22, 23) . As in the GGTase-I expression construct, the first 13-aa codons of the ␣ subunit were changed to improve translation and maintain the natural amino acid sequence. FTase was purified by using the same method as described previously for GGTase-I (23), with the following modifications. The YL1͞2 antibody CNBr Sepharose fast f low column (Amersham Pharmacia) was scaled up to 200 ml and run without detergent. Both the elution buffer and lysis buffer contained the protease inhibitors benzamide at 10 g͞ml, and aprotinin, leupeptin, and pepstatin at 5 g͞ml each. Pooled fractions were then loaded onto a Mono Q 16͞10 column (Amersham Pharmacia) and eluted by a gradient of 0 -300 mM NaCl in Mono Q buffer B (1 mM DTT͞50 mM Tris⅐HCl, pH 7.7). The peak FTase fractions were pooled and then combined with an equal volume of 2 M NH 4 SO 4 in Phenyl buffer B (100 mM Tris⅐HCl, pH 7.7͞10 mM DTT͞5 M ZnCl 2 ), loaded onto a Phenyl Superose 10͞10 column (Pharmacia) and eluted from a 1-0 M NH 4 SO 4 gradient in Phenyl buffer B. Peak fractions were pooled, desalted, and concentrated to 10 mg͞ml in 20 mM Tris⅐HCl (pH 7.7) containing 20 mM KCl, 10 M ZnCl, and 1 mM DTT.
Full-length recombinant rat FTase was expressed by using Sf9 cells, purified as described (24, 25) , and concentrated to 16 mg͞ml in 20 mM Tris⅐HCl (pH 7.7) containing 20 mM KCl, 10 M ZnCl, and 1 mM DTT. (27) . This method is particularly effective because the active site cavity is accessible via the solvent channels that run along the crystallographic six-fold axis.
Crystals were transferred stepwise into cryoprotectant solutions [stabilization solution with 43% (wt͞vol) PEG-8000 and 20% (wt͞vol) sucrose] containing additional peptide͞ peptidomimetic and FPP͞FPP analog molecules at 20 M concentrations and flash-cooled.
Crystallographic Data Collection, Structure Determination, and Refinement. Diffraction data were measured at 98 K with an R-axis IV image plate system (Molecular Structure, The Woodlands, TX) mounted on a Rigaku (Tokyo) RU-200 rotating anode generator with double mirror optics (Molecular Structure). DENZO and SCALEPACK were used for data reduction and scaling (28) .
All of the crystals belong to the space group P6 1 and contain one molecule of FTase per asymmetric unit. Initial phases for the human FTase complex were obtained by molecular replacement in X-PLOR (29) by using the 2.0-Å crystal structure of rat FTase with bound FPP analog and KKKSKTKCVIM peptide as a The residues that differ between rat and human FTase were consistent with F O -F C electron density and were changed to their human counterparts in the model. Difference electron density in the active site of human FTase clearly indicated the presence of well ordered FPP and L-739,750 molecules. The refined model of human FTase contains ␣ subunit residues 55-367 and ␤ subunit residues 17-423, which have continuous, well-defined electron density. As in all structures of FTase determined to date, the proline-rich region of 54 aa at the N terminus of the ␣ subunit is disordered.
Initial phases for the two structures with rat FTase were determined by molecular replacement. There is continuous well-defined electron density for all of the ligand molecules in each of the structures (Fig. 2B, Table 1) . Phase calculation and model refinement were done in X-PLOR (29) with a bulk solvent correction (30) . 
Results and Discussion
Structures of ternary complexes of human FTase with the non-substrate peptidomimetic inhibitor L-739,750 and FPP substrate, rat FTase with the non-substrate inhibitor tetrapeptide CVFM and FPP substrate, and with hexapeptide TKCVFM substrate and a nonreactive FPP analog were determined by x-ray crystallographic methods (Table 1 ; Fig. 1 ). In addition, the previously determined complex of rat FTase with TKCVIM is used for structural comparisons (18) . Addition of two amino acids at the N terminus in the TKCVFM hexapeptide, converts the CVFM non-substrate inhibitory peptide into an active substrate § (9) . L-739,750 is a peptidomimetic based on the non-substrate tetrapeptide inhibitor CIFM, but in which the two N-terminal peptide bonds have been replaced with amine or ether linkages (15) . These changes introduce extra rotational degrees of freedom in the peptidomimetic compared with a tetrapeptide (Fig. 1) . L-739,750 was designed before any structural information about FTase was available and consequently was developed by using well-established empirical approaches of medicinal chemistry.
Rat FTase was used to determine two of the three complexes reported in this study, because rat FTase crystallized more readily and reproducibly than human FTase. Comparison of rat and human structures is valid because the structural differences are limited to regions of crystal contact, and there is complete sequence and structural conservation in the active sites (see below).
Structure of Human FTase. The structure of human FTase is essentially identical to that of the previously reported rat enzyme (24) . Structural differences are largely accounted for by replacing the amino acid side chains in the rat structure with § Farnesylation of the peptides TKCVIM, TKCVFM, and CIIS has been demonstrated in this study; FTase did not farnesylate the tetrapeptide CVFM or L-739,750 (data not shown). those corresponding to the human sequence. The only significant differences between rat and human FTase structures occur at inter-protein contact points in the crystal lattice, which is consistent with the differences in crystallization properties of these two enzymes. Three regions of crystal contact involving ␣ subunit residues 55-79, and ␤ subunit residues 17-22 and 60 -72 have rms deviations of 1.5 Å, 10.1 Å, and 5.2 Å with the rat enzyme (PDB I.D. code 1D8D), respectively. Outside of these regions, the rat and human structures superimpose with an rms deviation of 0.4 Å. The structure of human FTase with bound L-739,750 peptidomimetic is shown in Fig. 2 A. Of the 44-aa differences between rat and human FTase, 25 are in the regions of subunit termini that are disordered in both crystals and therefore could not be visualized. All of the remaining 19 differences lie outside of the active site, many occurring on loops that connect pairs of helices in the ␣ subunit. Furthermore, all of the residues that interact with isoprenoid molecules, peptide substrates, and inhibitors in the structures of FTase complexes are conserved between these species and are in nearly identical conformations (17, 18, 27, 31) . This structural and sequence conservation indicates that either enzyme serves well for development and optimization of FTase inhibitors.
L-739,750 Peptidomimetic Conformation. The peptidomimetic inhibitor L-739,750 ( Fig. 1) (13, 16) , which is intended to mimic the tetrapeptide CIFM, adopts an extended conformation in the active site of FTase rather than the ␤-turn observed in NMR studies (16) . Coordination of the N-terminal cysteine thiol(ate) to the catalytic zinc ion is preserved in this peptidomimetic complex (Fig. 2C) . The carboxyl terminus of the peptidomimetic makes the same hydrogen bonding interactions with FTase as peptide substrates (17, 18) . FPP adopts the same conformation as seen in all other FTase complexes with bound FPP substrate (17, 27, 31) and shares the same conformation as FPP analogs, except for differences among these analogs within the first isoprene unit (17, 18) . The FPP interacts extensively with L-739,750 (Fig. 2) . The structure of the part of the peptidomimetic that corresponds to the a 2 X portion of the Ca 1 a 2 X motif is nearly identical to that observed in substrates (0.7 Å rms deviation with the K-Ras4B-derived peptide substrate TKCVIM for corresponding atoms; ref. 18 ). This region forms the same interactions with FTase as observed in cognate peptide substrates (refs. 17 and 18). The oxygen atoms of the sulfone substitution in the methionine side chain of L-739,750 form hydrogen bonds with Ser-99␤ and Trp-102␤ (Fig. 2C) . The phenylalanine residue of L-739,750 has extensive van der Waals interactions with Tyr-361␤, Trp-102␤, and Trp-106␤, as well as the isoprenoid of FPP.
The most striking conformational difference compared with the peptide substrate is within the N-terminal Ca 1 portion of Ca 1 a 2 X peptidomimetic. This portion of the peptidomimetic has a 2.2 Å rms deviation with the TKCVIM peptide substrate for analogous atoms, by virtue of a change in the backbone angles between the a 2 and a 1 positions. As a result, the positively charged N terminus of L-739,750 forms an ion pair with an ␣-phosphate oxygen of the FPP substrate (Fig. 3A) , an interaction that is not present in longer peptide substrates or proteins for the simple reason that their N termini are further away (Fig.  3B) . The thiol(ate) of the N-terminal cysteine is located in a position identical to that observed in substrates, thereby retaining the bond to the zinc, but the cysteine adopts a different rotamer to maintain this bond. In the non-substrate conformation, the N-terminal moiety is juxtaposed between the zinc and FPP, changing the geometry of the thiol C ␤ -S ␥ bond, which now points away from the FPP substrate. Consequently, the interaction between the reactive groups of the two substrates has been altered radically.
Non-Substrate Tetrapeptide CVFM Conformation. The non-substrate CVFM tetrapeptide adopts the same conformation as L-739,750, with an rms deviation of 0.6 Å for analogous atoms (Fig. 3A) . This result indicates that L-739,750 truly mimics the tetrapeptide despite the increased torsional flexibility of L-739,750. Furthermore, the CVFM peptide also forms an ion pair between its N terminus and the FPP ␣-phosphate. As is the case for L-739,750, the structure of the part of the CVFM tetrapeptide corresponding to the a 2 X portion of the Ca 1 a 2 X motif is nearly identical to that observed in the K-Ras4B-derived peptide substrate TKCVIM (0.28 Å rms deviation for corresponding atoms). Although the backbone conformation of the X residue is the same between these two peptides, there is a difference between the TKCVIM substrate and CVFM non-substrate peptides in the ͞ backbone Ramachandran angles of the a 2 residue (Table 2) . This difference is to be an important factor determining the farnesylation of CaaX tetrapeptides (see below).
Hexapeptide Substrate TKCVFM Conformation. The TKCVFM peptide adopts the same conformation as the K-Ras4B-derived peptide substrate TKCVIM in an analogous complex (ref. 18 ; Fig. 3B ), consistent with the observation that it is also a substrate (9, 32). The two hexapeptides have an rms deviation of 0.38 Å for superimposable atoms. The valine residue at the a 1 position has a different side chain rotamer conformation, which is correlated with a concerted change in the conformation of the first isoprene unit of the FPP analog, thereby accommodating steric packing interactions between the FPP 
where ͗I͘ is the average intensity of multiple measurements. R factor and R free ϭ (⌺͉Fobs Ϫ Fcalc͉)͞(⌺͉Fobs͉). Rfree was calculated using the same Ϸ5% of structure factors from each data set that were held aside during refinement.
analog and amino acid side chain (Fig. 3B , Table 2 ). As with the L-739,750 peptidomimetic, the only significant deviations between CVFM and TKCVFM are at the N terminus of the tetrapeptide (Fig. 3C ). This result strongly suggests that Nterminal interaction with the FPP ␣-phosphate is the dominant determinant of CaaX tetrapeptide farnesylation, consistent with biochemical observations (9).
Structural Basis of CaaX Peptidomimetic Inhibition. We propose that certain tetrapeptides are not able to act as substrates because they bind in a nonproductive conformation that is stabilized by an ion pair formed between their N terminus and the FPP ␣-phosphate. This conformation radically alters the geometry of the cysteine, despite the maintenance of the Zn-thiol(ate) bond, and interferes with the formation of the transition state required for catalysis. The sequence determinants that distinguish tetrapeptide substrates from non-substrates are subtle, and appear to involve destabilizing interactions that prevent peptides from becoming non-substrates, rather than stabilizing interactions that promote formation of a non-productive complex. The critical change in backbone geometry that determines whether a tetrapeptide adopts a substrate or non-substrate conformation occurs in the backbone geometry between residues in the a 1 and a 2 positions. The side chains in the a 2 position adopt essentially the same conformation in all peptides, thereby filling a complementary hydrophobic pocket in the protein. This side-conformation places steric constraints on the backbone angle (defined as the torsion involving atoms C i-1 , N i , ␣ C i , and C i ) between the a 1 and a 2 residues. ␤-branched amino acids (isoleucine and valine) in the a 2 position form an unfavorable steric interaction between their C ␥2 methyl group and the carbonyl oxygen of the a 1 residue in the non-substrate backbone conformation adopted by the CVFM peptide (Fig.  3D) . Conformational mapping calculations indicate that tetrapeptides with isoleucine or valine residues in the a 2 position cannot adopt the non-substrate conformation, whereas no unfavorable interactions are formed in the substrate conformation (Fig. 4) . By contrast, these calculations show that peptides with a phenylalanine, alanine, or leucine in this position can adopt either conformation without forming unfavorable interactions.
Tetrapeptides with ␤-branched amino acids in the a 2 position (such as isoleucine in CVIM) therefore are obligate substrates, because on steric grounds they cannot adopt the (Fig. 1) , which are colored according to their observed conformations with these peptides. (C) Comparison of the hexapeptide substrate TKCVFM and the non-substrate tetrapeptide inhibitor CVFM. A boxed region highlights the differences between the substrate and non-substrate conformations. (D) Energetically unfavorable steric contact (red spikes) between the C ␥2 methyl group of the isoleucine residue in the a2 position and the carbonyl oxygen of the a1 residue when the phenylalanine residue of the CVFM tetrapeptide is replaced with isoleucine. Consequently, a tetrapeptide with a ␤-branched residue (isoleucine or valine) in the a2 position cannot adopt the non-substrate binding mode observed for CVFM. These steric contacts were displayed by using the programs PROBE and REDUCE (34) non-substrate conformation corresponding to the CVFM tetrapeptide. Amino acids that are not branched at this position can adopt either the substrate or non-substrate conformation, the latter being preferentially stabilized by formation of the N-terminal ion pair with the FPP ␣-phosphate. In such peptides, an equilibrium between the substrate and non-substrate conformations must therefore exist. We therefore predict that, of the CaaX cognate tetrapeptides, only peptides with isoleucine or valine in the a 2 position are substrates, whereas peptides with other aliphatic amino acids that are not ␤-branched are poor or non-substrates (provided that the N terminus is not blocked). This interpretation is also consistent with the observation that CaaX tetrapeptide mimetics that have a ␤-branched side chain in the a 2 position are nonsubstrate inhibitors if the two N-terminal peptide bonds are reduced, eliminating the carbonyl oxygen of the a 1 residue [e.g., the non-substrate peptidomimetic L-731,735 derived from the tetrapeptide substrate CIIS (11, 33) ]. A detailed understanding of the sequence determinants of steric interactions will facilitate further design of more effective FTase inhibitors. Fig. 4 . Conformational maps comparing placement of isoleucine (solid line) and phenylalanine (dashed line) in the a 2 position of a tetrapeptide that adopts a non-substrate conformation. The coordinates of the CVFM peptide complex were used as a representative non-substrate conformation. Only the a 1a2 dipeptide was considered in the calculation. Shown are the contributions to the van der Waals interactions as the dihedral angle between the a 1 and a 2 positions is varied. For each sampled value of this angle, the 1 dihedral angles of the side chains in the a 1 (valine) and a2 (isoleucine, valine, phenylalanine, leucine, or alanine) positions were allowed to vary within Ϯ30°of the values observed in the crystal structure, and the minimum local energy was recorded. In the a 2 position, valine resulted in a curve similar to isoleucine, whereas leucine and alanine yielded curves similar to phenylalanine (not shown). The shaded areas indicate the two regions in the vicinity of the non-substrate ( ϭ Ϫ154°, arrow) and substrate ( ϭ Ϫ126°, arrow) conformations, respectively (the conformational map outside these regions is not relevant, because the tetrapeptide is not observed to adopt such conformations in the FTase active site). Conformational maps were generated by using the DEZYMER program (36, 37) .
